Cargando…

The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C

Hepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a...

Descripción completa

Detalles Bibliográficos
Autores principales: van Buuren, Nicholas, Fradette, Lorraine, Grebely, Jason, King, Alexandra, Krajden, Mel, MacParland, Sonya A., Marshall, Alison, Saeed, Sahar, Wilson, Joyce, Klein, Marina B., Sagan, Selena M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098058/
https://www.ncbi.nlm.nih.gov/pubmed/27843889
http://dx.doi.org/10.1155/2016/7603526
_version_ 1782465706768465920
author van Buuren, Nicholas
Fradette, Lorraine
Grebely, Jason
King, Alexandra
Krajden, Mel
MacParland, Sonya A.
Marshall, Alison
Saeed, Sahar
Wilson, Joyce
Klein, Marina B.
Sagan, Selena M.
author_facet van Buuren, Nicholas
Fradette, Lorraine
Grebely, Jason
King, Alexandra
Krajden, Mel
MacParland, Sonya A.
Marshall, Alison
Saeed, Sahar
Wilson, Joyce
Klein, Marina B.
Sagan, Selena M.
author_sort van Buuren, Nicholas
collection PubMed
description Hepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a priority and supported the establishment of a National Hepatitis C Research Network. In 2015, the introduction of new interferon- (IFN-) free therapies with high cure rates (>90%) and few side effects revolutionized HCV therapy. However, a considerable proportion of the population remains undiagnosed and treatment uptake remains low in Canada due to financial, geographical, cultural, and social barriers. Comprehensive prevention strategies, including enhanced harm reduction, broader screening, widespread treatment, and vaccine development, are far from being realized. The theme of the 2016 symposium, “We're not done yet: remaining challenges in Hepatitis C,” was focused on identifying strategies to enhance prevention, diagnosis, and treatment of HCV to reduce disease burden and ultimately eliminate HCV in Canada.
format Online
Article
Text
id pubmed-5098058
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-50980582016-11-14 The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C van Buuren, Nicholas Fradette, Lorraine Grebely, Jason King, Alexandra Krajden, Mel MacParland, Sonya A. Marshall, Alison Saeed, Sahar Wilson, Joyce Klein, Marina B. Sagan, Selena M. Can J Gastroenterol Hepatol Commentary Hepatitis C virus (HCV) affects approximately 268,000 Canadians and results in more years of life lost than any other infectious disease in the country. Both the Canadian Institutes of Health Research (CIHR) and the Public Health Agency of Canada (PHAC) have identified HCV-related liver disease as a priority and supported the establishment of a National Hepatitis C Research Network. In 2015, the introduction of new interferon- (IFN-) free therapies with high cure rates (>90%) and few side effects revolutionized HCV therapy. However, a considerable proportion of the population remains undiagnosed and treatment uptake remains low in Canada due to financial, geographical, cultural, and social barriers. Comprehensive prevention strategies, including enhanced harm reduction, broader screening, widespread treatment, and vaccine development, are far from being realized. The theme of the 2016 symposium, “We're not done yet: remaining challenges in Hepatitis C,” was focused on identifying strategies to enhance prevention, diagnosis, and treatment of HCV to reduce disease burden and ultimately eliminate HCV in Canada. Hindawi Publishing Corporation 2016 2016-10-24 /pmc/articles/PMC5098058/ /pubmed/27843889 http://dx.doi.org/10.1155/2016/7603526 Text en Copyright © 2016 Nicholas van Buuren et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
van Buuren, Nicholas
Fradette, Lorraine
Grebely, Jason
King, Alexandra
Krajden, Mel
MacParland, Sonya A.
Marshall, Alison
Saeed, Sahar
Wilson, Joyce
Klein, Marina B.
Sagan, Selena M.
The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C
title The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C
title_full The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C
title_fullStr The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C
title_full_unstemmed The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C
title_short The 5th Canadian Symposium on Hepatitis C Virus: We Are Not Done Yet—Remaining Challenges in Hepatitis C
title_sort 5th canadian symposium on hepatitis c virus: we are not done yet—remaining challenges in hepatitis c
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098058/
https://www.ncbi.nlm.nih.gov/pubmed/27843889
http://dx.doi.org/10.1155/2016/7603526
work_keys_str_mv AT vanbuurennicholas the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT fradettelorraine the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT grebelyjason the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT kingalexandra the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT krajdenmel the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT macparlandsonyaa the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT marshallalison the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT saeedsahar the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT wilsonjoyce the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT kleinmarinab the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT saganselenam the5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT vanbuurennicholas 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT fradettelorraine 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT grebelyjason 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT kingalexandra 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT krajdenmel 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT macparlandsonyaa 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT marshallalison 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT saeedsahar 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT wilsonjoyce 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT kleinmarinab 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc
AT saganselenam 5thcanadiansymposiumonhepatitiscviruswearenotdoneyetremainingchallengesinhepatitisc